Question follow-through · 63803
Blood: Contamination
To ask the Minister for the Cabinet Office, what discussions he has had with the Secretary of State for Health and Social Care on compensation for people impacted by infected blood and also by variant Creutzfeldt-Jakob disease.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Cabinet Office
- Tabled
- 30 Jun 2025
- Target answer date
- 2 Jul 2025
- Answer
- 8 Jul 2025 · 8 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
30 Jun 2025
Question tabled
To ask the Minister for the Cabinet Office, what discussions he has had with the Secretary of State for Health and Social Care on compensation for people impacted by infected blood and also by variant Creutzfeldt-Jakob disease.
2 Jul 2025
Target answer date
Date supplied by the official written-questions record.
8 Jul 2025
Answer published
In his 2022 Compensation Framework Study, Sir Robert Francis recommended that variant Creutzfeldt-Jakob Disease (vCJD) was not included in the Infected Blood Compensation Scheme. He noted that “this is a rare disease for which there is a separate compensa...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.